LTRN · Lantern Pharma Inc. · Share Buybacks
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern in the absence of obtaining substantial additional funding. While the Company plans to pursue periodic capital raises, including additional potential sales under the ATM, as well as potential collaborations, grant funding and other opportunities to extend the Company's operating runway, no assurance can be given that sufficient funding will be available when needed to allow the Company to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2025-07-03 | — | $15,530,000 | — | — | 8-K , filed 2026-03-30 |
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2023-12-31 | $499,997 | 10-K, filed 2025-03-27 |
| 2022-12-31 | $2,482,286 | 10-K, filed 2024-03-18 |
| 2021-12-31 | $939,666 | 10-K, filed 2023-03-20 |